Decision: Favourable

Decisions Table

Study Title:

Phase 2, randomized, parallel-group, double-blind, placebocontrolled study of sonelokimab in patients with active moderate to severe hidradenitis suppurativa

  • NREC Code:

    22-NREC-CT-130

  • Decision:

    Favourable

  • Meeting Date:

    27/07/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Brian Kirby

  • PI Institution:

    SVUH

  • Sponsor:

    MoonLake Immunotherapeutics AG

Scroll to Top